Business
CNS Pharmaceuticals Announces Contract with International GMP Manufacturer for Production of Berubicin
This Additional Production Will Ensure Availability Through the Completion of its Upcoming Phase II Clinical Trials HOUSTON, Jan. 14, 2020 /PRNewswire/ -- CNS
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"This Additional Production Will Ensure Availability Through the Completion of its Upcoming Phase II Clinical Trials\n\n\nHOUSTON, Jan. 14, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has signed a contract with NCK A/S for the large scale production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors.\nNCK A/S is a GMP manufacturer of complex drugs located in Farum, Denmark, and the previous producer of Berubicin for Reata Pharmaceuticals. Production of large scale Berubicin is set to commence in January and will ensure drug availability through the end of Phase II clinical trials for glioblastoma.\n\"We are extremely excited to have entered into a contract with NCK A/S. We believe working with an experienced company in the production of this class of anthracyclines is paramount given the complex chemistry and difficulty to produce very high purity for human use,\" stated John Climaco, CEO of CNS Pharmaceuticals. \"We are confident in NCK A/S' ability to succeed in the large scale production of our lead candidate due to its extensive experience in Berubicin synthesis for previous clinical trials. This contract represents a key stride in the development of Berubicin and secures drug availability as we look forward not only to initiate but also expand Phase II clinical trials later this year.\"\nAbout BerubicinBerubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin was developed at the MD Anderson Cancer Center (MDACC), which is the top ranked cancer center in the US, and largest cancer research and treatment facility in the world. Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata. \nAbout CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a ...